中国临床药理学杂志2017，Vol.33Issue(18)：1813-1816,4.DOI:10.13699/j.cnki.1001-6821.2017.18.023
氯氮平片联合利培酮片治疗难治性精神分裂症安全性的系统评价
Systematic review of the safety profile of clozapine tablets combined risperidone tablets on refractory schizophrenia
摘要
Abstract
Objective To evaluate the safety profile of clozapine tablets combined risperidone tablets for refractory schizophrenia.Methods We searched Medline,EmBase,CBM in both English and Chinese from the date of their establishment to November 30th,2016,for randomized controlled trials (RCTs),quasi randomized controlled trials (Quasi-RCTs) about clozapine combined risperidone for refractory schizophrenia.Treatment group received clozapine combined risperidone.Control group received clozapine alone.Quality assessment and data extraction were conducted with the Cochrane Collaboration's RevMan 5.1.0 software.Results A total of 9 trials involving 781 patients met the inclusion criteria.Results showed that the safety of clozapine combined risperidone most superior to clozapoine alone (P ＜ 0.05),except for acute dystonia,akathisia and tremor(P ＞ 0.05).Conclusion It was not just a simple addition for the clozapine combined risperidone.It may reduce the incidence of adverse reaction caused by high dose,and had a higher security.So it could be used as one of the treatment strategies for the refractory schizophrenia.关键词
氯氮平/利培酮/难治性精神分裂症/安全性/Meta分析Key words
clozapine/risperidone/refractory schizophrenia/safety/Meta-analysis分类
医药卫生引用本文复制引用
李媛媛,张云淑,王红英,栗克清..氯氮平片联合利培酮片治疗难治性精神分裂症安全性的系统评价[J].中国临床药理学杂志,2017,33(18):1813-1816,4.基金项目
河北省青年基金资助项目(20120254) （20120254）
